The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 19, 2017

Filed:

Jan. 08, 2016
Applicant:

The University of North Carolina AT Charlotte, Charlotte, NC (US);

Inventor:

Pinku Mukherjee, Waxhaw, NC (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/30 (2006.01); A61K 49/00 (2006.01); A61K 31/7088 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3092 (2013.01); A61K 31/7088 (2013.01); A61K 39/39558 (2013.01); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6859 (2017.08); A61K 49/0002 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2821 (2013.01); C07K 16/2866 (2013.01); C07K 16/30 (2013.01); G01N 33/57438 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/41 (2013.01); C07K 2319/60 (2013.01);
Abstract

Provided are isolated nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens. Also provided are isolated polypeptides and CARs encoded by the isolated nucleic acid molecules, vectors that include the isolated nucleic acid molecules, cells that include the isolated nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered T cells in a subject, expanding a population of genetically engineered T cells in a subject, modulating the amount of cytokine secreted by a T cell, reducing the amount of activation-induced calcium influx into a T cell, providing an anti-tumor immunity to a subject, treating a mammal having a MUC1-associated disease or disorder, stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, and imaging a MUC1-associated tumor.


Find Patent Forward Citations

Loading…